Research programme: T-type calcium channel antagonists - Merck
Alternative Names: TTA-1; TTA-2; TTA-3; TTA-A2; TTA-P2Latest Information Update: 16 Jul 2016
At a glance
- Originator Merck & Co
- Class Acetamides; Piperidines
- Mechanism of Action T-type calcium channel antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Epilepsy; Pain; Sleep disorders; Smoking withdrawal
- Discontinued Stroke
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Epilepsy in USA (PO)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Pain in USA (PO)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Sleep-disorders in USA (PO)